Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial-Reference-Cited by-同舟云学术

Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

Published:2021-12-25 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Cadegiani Flavio A,Zimerman Ricardo A,Fonseca Daniel N,Correia Michael N,Muller Marcio P,Bet Diego Leonardo,Slaviero Marcio Rafael,Zardo Ivan,Benites Paulo Roberto,Barros Renan N,Paulain Raysa W,Onety Dirce C,Israel Karla Cristina P,Gustavo Wambier Carlos,Goren Andy

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference61 articles.

1. Impact of sex and gender on COVID-19 outcomes in Europe;Gebhard C;Biol Sex Differ,2020

2. COVID-19 clinical features;McIntosh K,2021

3. Male balding is a major risk factor for severe COVID-19;Lee J;J Am Acad Dermatol,2020

4. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the "Gabrin sign";Wambier CG;J Am Acad Dermatol,2020

5. Alopecia and severity of COVID-19: a cross-sectional study in Peru;Salazar Arenas MÁ;Infez Med,2021

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiandrogens as Therapies for COVID-19: A Systematic Review;Cancers;2024-01-10

2. Molecules for COVID-19 treatment;Chinese Chemical Letters;2023-12

3. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response;Proceedings of the National Academy of Sciences;2023-07-17

4. Antiandrogen agents in COVID-19: a meta-analysis of randomized trials;Minerva Medica;2023-05

5. Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature;Journal of Clinical Laboratory Analysis;2023-04